Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
LONDON and PHILADELPHIA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics AIM:AVCT, a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced the appointment of the seasoned biotech executive Mr. Mats Blom as a member of i…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.